Virtual Library

Start Your Search

Michela Pilati



Author of

  • +

    P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.01-14 - Immunotherapy (I) for Advanced, Pre-Treated, Non-Squamous NSCLC (APNS-NSCLC). Preliminary Data of a Pooled Analysis (ID 13469)

      16:45 - 18:00  |  Author(s): Michela Pilati

      • Abstract
      • Slides

      Background

      Background. To assess the role of I for second line treatment of APNS-NSCLC.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Methods. A pooled analysis of the final data of the CA209057, the KEYNOTE-010 and the OAK trial was performed. Overall Survival (OS) was the primary end point of the trial. The outcomes of patients with PD-L1 expression of 1%-49% (PD-L1 1%-49%), PD-L1 expression <1% (PD-L1<1%) or mutated-EGFR (EGFR+) were analyzed comparing any checkpoint inhibitor with standard chemotherapy. An indirect comparison with network meta-analysis was performed between the different checkpoint inhibitors whenever a significant difference was observed in the pooled analysis. Direct and indirect comparisons were performed using a random effect model.

      4c3880bb027f159e801041b1021e88e8 Result

      Results. The outcome of 1720 patients was analyzed. 313 patients had been treated with Atezolizumab (A), 292 with Nivolumab (N), 270 with Pembrolizumab (P), and 845 with Docetaxel (D). The preliminary results were detailed in the table.

      Legend. CI95%: 95% Confidence Interval; *: Pooled Analysis; **: Network Meta-Analysis.

      OS Hazard Ratio

      CI95%

      A vs D (PD-L1 1%-49%)

      0.571

      0.423-0.771

      P<0.001

      N vs D (PD-L1 1%-49%)

      0.62

      0.467-0.882

      P=0.001

      P vs D (PD-L1 1%-49%)

      0.76

      0.604-0.956

      P=0.019

      I vs D (PD-L1 1%-49%)*

      0.66

      0.555-0.786

      P<0.001

      A vs N (PD-L1 1%-49%)**

      0.921

      0.609-1.392

      P=0.696

      A vs P (PD-L1 1%-49%)**

      0.751

      0.541-1.043

      P=0.087

      N vs P (PD-L1 1%-49%)**

      0.816

      0.597-1.116

      P=0.491

      N vs D (PD-L1<1%)

      0.9

      0.66-1.214

      P=0.491

      A vs D (PD-L1<1%)

      1.04

      0.619-1.747

      P=0.882

      I vs D (PD-L1<1%)*

      0.933

      0.72-1.21

      P=0.601

      P vs D (EGFR+)

      0.88

      0.453-1.71

      P=0.706

      N vs D (EGFR+)

      1.18

      0.693-2.004

      P=0.542

      I vs S (EGFR+)*

      1.052

      0.695-1.594

      P=0.81

      8eea62084ca7e541d918e823422bd82e Conclusion

      Conclusions. Our data seem to confirm the role of I for APNS-NSCLC with PD-L1 1%-49%. On the contrary, not-significant benefits in terms of OS seem to emerge for patients with PD-L1<1% or EGFR+ expression. Likewise, no significant differences seem to emerge from the indirect comparisons between A, N and P for patients with a PD-L1 1%-49% expression. Although all these data need to be analyzed with caution, as expression of indirect comparisons, waiting further conformations from clinical trials they can support clinicians for daily clinical practice.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.